Regarding targeted glycolysis metabolism, we mainly approach it from two aspects: one is to enhance the efficacy of anti-PD-L1/PD-1 by altering the glucose metabolism of non-tumor cells such as immune cells and tumor vascular endothelial cells; the other is to directly impact tumor cell glycolysis to augment anti-PD-L1/PD-1 efficacy, with more research currently focused on the latter151,152. The gene discussed is CD274; the disease is neoplasm.